GERCOR-TOURNIGAND

Regimen

Experimental
FOLFIRI → FOLFOX6 (upon progression)
Control
FOLFOX6 → FOLFIRI (upon progression)

Population

Metastatic CRC, 1L/2L sequential, previously untreated; comparing optimal sequence of FOLFIRI and FOLFOX6.

Key finding

1L mCRC: mOS 21.5 mo (arm A) vs 20.6 mo (arm B) (p=0.99); FOLFIRI 1L: RR 56%, mPFS 8.5 mo; FOLFOX6 1L: RR 54%, mPFS 8.0 mo (p=0.26); both sequences yielded equivalent outcomes; FOLFIRI→FOLFOX6 second-line PFS superior (4.2 vs 2.5 mo)

Source: PMID 14657227

Timeline

    Guideline citations

    • NCCN Colon (p.13)
    • NCCN Rectal (p.76)